Features of the Metabolic Syndrome and Subclinical Atherosclerosis in Patients with Cerebrotendinous Xanthomatosis: An Augmented Risk for Premature Cardiovascular Disease

Overview

Journal Front Genet

Date 2022 Oct 14

PMID 36238157

Authors

H Cohen

S Hassin-Baer

A Shaish

Affiliations

Soon will be listed here.

Abstract

Cerebrotendinous xanthomatosis (CTX) is a rare lipid storage disease, caused by deficiency of sterol-27-hydroxylase. Xanthomatous lesions in numerous tissues, and an elevation of cholestanol levels, characterize the disease. Its natural course is progressive neurologic deterioration, leading to premature death. Chronic treatment with oral chenodeoxycholic acid (CDCA) reduces cholestanol levels. Occurrence of premature atherosclerosis has been described in CTX in an unknown mechanism. The aim of the current work was to evaluate the potential metabolic abnormalities and preclinical vascular changes in Israeli CTX patients. Ten subjects with CTX were studied. Features of the metabolic syndrome were evaluated, and carotid intima media thickness (cIMT) was measured in the common carotid arteries. All patients were diagnosed with CTX, and all received treatment with CDCA, which resulted in normalization of their plasma cholestanol levels. At the conclusion of the follow up, risk factors for CVD and features of MS were present in all the patients and in three patients, cIMT was higher compared to control subjects. Cardiovascular risk factors and premature vascular changes exist in young CTX patients and proper assessment should be implemented with preventive measures to reduce the risk of atherosclerotic cardiovascular disease in CTX patients.

References

von Bahr S, Movin T, Papadogiannakis N, Pikuleva I, Ronnow P, Diczfalusy U . Mechanism of accumulation of cholesterol and cholestanol in tendons and the role of sterol 27-hydroxylase (CYP27A1). Arterioscler Thromb Vasc Biol. 2002; 22(7):1129-35. DOI: 10.1161/01.atv.0000022600.61391.a5. View

Stein J, Korcarz C, Hurst R, Lonn E, Kendall C, Mohler E . Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for.... J Am Soc Echocardiogr. 2008; 21(2):93-111. DOI: 10.1016/j.echo.2007.11.011. View

Pahwa P, Chu L, Karunanayake C, Aich P, Hecker M, Saxena A . Predictive biomarkers of cardiovascular disease in adult Canadian population. J Diabetes Metab Disord. 2021; 20(2):1199-1209. PMC: 8630244. DOI: 10.1007/s40200-021-00842-y. View

Valdivielso P, Calandra S, Duran J, Garuti R, Herrera E, Gonzalez P . Coronary heart disease in a patient with cerebrotendinous xanthomatosis. J Intern Med. 2004; 255(6):680-3. DOI: 10.1111/j.1365-2796.2004.01316.x. View

Li Y, Iso H, Cui R, Murakami Y, Yatsuya H, Miura K . Serum γ-glutamyltransferase and Mortality due to Cardiovascular Disease in Japanese Men and Women. J Atheroscler Thromb. 2016; 23(7):792-9. PMC: 7399270. DOI: 10.5551/jat.32698. View

Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;.... Circulation. 2009; 120(16):1640-5. DOI: 10.1161/CIRCULATIONAHA.109.192644. View

Hunjadi M, Lamina C, Kahler P, Bernscherer T, Viikari J, Lehtimaki T . HDL cholesterol efflux capacity is inversely associated with subclinical cardiovascular risk markers in young adults: The cardiovascular risk in Young Finns study. Sci Rep. 2020; 10(1):19223. PMC: 7645719. DOI: 10.1038/s41598-020-76146-7. View

Verrips A, Dotti M, Mignarri A, Stelten B, Verma S, Federico A . The safety and effectiveness of chenodeoxycholic acid treatment in patients with cerebrotendinous xanthomatosis: two retrospective cohort studies. Neurol Sci. 2019; 41(4):943-949. PMC: 7160076. DOI: 10.1007/s10072-019-04169-8. View

Rahmani J, Miri A, Namjoo I, Zamaninour N, Maljaei M, Zhou K . Elevated liver enzymes and cardiovascular mortality: a systematic review and dose-response meta-analysis of more than one million participants. Eur J Gastroenterol Hepatol. 2019; 31(5):555-562. DOI: 10.1097/MEG.0000000000001353. View

10.

Lazarevic S, danic M, Golocorbin-Kon S, Al-Salami H, Mikov M . Semisynthetic bile acids: a new therapeutic option for metabolic syndrome. Pharmacol Res. 2019; 146:104333. DOI: 10.1016/j.phrs.2019.104333. View

11.

Yahalom G, Tsabari R, Molshatzki N, Ephraty L, Cohen H, Hassin-Baer S . Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis. Clin Neuropharmacol. 2013; 36(3):78-83. DOI: 10.1097/WNF.0b013e318288076a. View

12.

Nakamura T, Matsuzawa Y, Takemura K, Kubo M, Miki H, Tarui S . Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis. Metabolism. 1991; 40(7):741-6. DOI: 10.1016/0026-0495(91)90094-d. View

13.

Duell P, Salen G, Eichler F, DeBarber A, Connor S, Casaday L . Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis. J Clin Lipidol. 2018; 12(5):1169-1178. DOI: 10.1016/j.jacl.2018.06.008. View

14.

Twig G, Reichman B, Afek A, Derazne E, Hamiel U, Furer A . Severe obesity and cardio-metabolic comorbidities: a nationwide study of 2.8 million adolescents. Int J Obes (Lond). 2018; 43(7):1391-1399. DOI: 10.1038/s41366-018-0213-z. View

15.

Souto M, Almeida-Santos M, Ferreira E, Goncalves L, Oliveira J, Sousa A . Spontaneous Coronary Artery Dissection in a Patient with Cerebrotendinous Xanthomatosis. Arq Bras Cardiol. 2020; 115(1 suppl 1):18-21. PMC: 8386949. DOI: 10.36660/abc.20190456. View

16.

Moghadasian M, Salen G, Frohlich J, Scudamore C . Cerebrotendinous xanthomatosis: a rare disease with diverse manifestations. Arch Neurol. 2002; 59(4):527-9. DOI: 10.1001/archneur.59.4.527. View

17.

Liu D, Du C, Shao W, Ma G . Diagnostic Role of Carotid Intima-Media Thickness for Coronary Artery Disease: A Meta-Analysis. Biomed Res Int. 2020; 2020:9879463. PMC: 7063191. DOI: 10.1155/2020/9879463. View

18.

Minelli S, Minelli P, Montinari M . Reflections on Atherosclerosis: Lesson from the Past and Future Research Directions. J Multidiscip Healthc. 2020; 13:621-633. PMC: 7398886. DOI: 10.2147/JMDH.S254016. View

19.

Tao Q, Zhang Y, Lin H, Dong H, Ni W, Wu Z . Clinical and genetic characteristics of Chinese patients with cerebrotendinous xanthomatosis. Orphanet J Rare Dis. 2019; 14(1):282. PMC: 6892200. DOI: 10.1186/s13023-019-1252-9. View

20.

Kuriyama M, Fujiyama J, Yoshidome H, Takenaga S, Matsumuro K, Kasama T . Cerebrotendinous xanthomatosis: clinical and biochemical evaluation of eight patients and review of the literature. J Neurol Sci. 1991; 102(2):225-32. DOI: 10.1016/0022-510x(91)90073-g. View